Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gritstone Oncology stock

Own Gritstone Oncology stock in just a few minutes.

Gritstone Oncology, Inc is a biotechnology business based in the US. Gritstone Oncology shares (GRTS) are listed on the NASDAQ and all prices are listed in US Dollars. Gritstone Oncology employs 169 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Gritstone Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRTS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Gritstone Oncology share price

Use our graph to track the performance of GRTS stocks over time.

Gritstone Oncology shares at a glance

Information last updated 2021-04-29.
52-week range$2.54 - $28.52
50-day moving average $10.78
200-day moving average $8.68
Wall St. target price$25.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.21

Buy Gritstone Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gritstone Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gritstone Oncology financials

Revenue TTM $4 million
Gross profit TTM $-84,606,000
Return on assets TTM -32.64%
Return on equity TTM -69.96%
Profit margin 0%
Book value $3.51
Market capitalisation $471.4 million

TTM: trailing 12 months

Shorting Gritstone Oncology shares

There are currently 4.2 million Gritstone Oncology shares held short by investors – that's known as Gritstone Oncology's "short interest". This figure is 34% up from 3.1 million last month.

There are a few different ways that this level of interest in shorting Gritstone Oncology shares can be evaluated.

Gritstone Oncology's "short interest ratio" (SIR)

Gritstone Oncology's "short interest ratio" (SIR) is the quantity of Gritstone Oncology shares currently shorted divided by the average quantity of Gritstone Oncology shares traded daily (recently around 1.2 million). Gritstone Oncology's SIR currently stands at 3.36. In other words for every 100,000 Gritstone Oncology shares traded daily on the market, roughly 3360 shares are currently held short.

However Gritstone Oncology's short interest can also be evaluated against the total number of Gritstone Oncology shares, or, against the total number of tradable Gritstone Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gritstone Oncology's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Gritstone Oncology shares in existence, roughly 90 shares are currently held short) or 0.1171% of the tradable shares (for every 100,000 tradable Gritstone Oncology shares, roughly 117 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gritstone Oncology.

Find out more about how you can short Gritstone Oncology stock.

Gritstone Oncology share dividends

We're not expecting Gritstone Oncology to pay a dividend over the next 12 months.

Gritstone Oncology share price volatility

Over the last 12 months, Gritstone Oncology's shares have ranged in value from as little as $2.535 up to $28.5215. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gritstone Oncology's is 0.1959. This would suggest that Gritstone Oncology's shares are less volatile than average (for this exchange).

Gritstone Oncology overview

Gritstone Oncology, Inc. , a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site